Proficiency Testing/EQA / 2020 Surveys / Genetics and Molecular Pathology / Biochemical and Molecular Genetics Help Please log in to determine if you are eligible to purchase PT Programs. MOLECULAR GENETICS SERIES - MGL2 Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS). Disease/Gene Challenges per Shipment Number of Shipments Cystic fibrosis (CFTR gene) 3 Two shipments per year DMD/Becker (DMD gene) 3 Friedreich ataxia (FXN gene) 3 Hemoglobin S/C 3 Huntington (HTT gene) 3 Myotonic dystrophy (DMPK gene) 3 RhD 3 Spinal muscular atrophy (SMN1 and SMN2 genes) 3 Spinocerebellar ataxia (ATXN1, ATXN2, ATXN3, CACNA1A, and ATXN7 genes) 3 Additional Information The cystic fibrosis program is designed for laboratories that are testing for the minimum mutation panel for population-based carrier screening (ie, the ACMG-23 mutation panel) from the ACMG Technical Standards and Guidelines for CFTR Mutation Testing, expanded panels, PolyT variant analysis, and/or full gene sequencing. Program Information Three 50.0‑μg extracted DNA specimens per disease/gene Shipping Schedule Shipment A: May 11 Shipment B: September 28 Guest Log in/Register